Where is Ceptaris Therapeutics headquartered?

Ceptaris Therapeutics is located in Malvern, Pennsylvania.

Who invested in Ceptaris Therapeutics?

Ceptaris Therapeutics has 13 investors including Geekdom Fund And Geekdom Fund.

How much funding has Ceptaris Therapeutics raised to date?

Ceptaris Therapeutics has raised ____.

When was the last funding round for Ceptaris Therapeutics?

Ceptaris Therapeutics closed its lastf unding roundon Jul 19, 2017 from a Convertible Note round.

Company Information
Company Timeline (Coming Soon)

ceptaris.com

Ceptaris Therapeutics

Ceptaris Therapeutics is a pharmaceutical company developing therapeutics for symptoms of early-stage mycosis fungoides.

Business Model: Non-Profit

Revenue: $0

Employees: 11-50

Rankings

Industries / Tags:

Detailed Ceptaris Therapeutics Information

M&A Details

Ceptaris Therapeutics was acquired by Actelion Pharmaceuticals.
The acquisition happend on 2013-07-31.
Details of the transaction were not public

Acquirer

Actelion Pharmaceuticals

General Information

Geographic Data

Address:

City: Malvern

State: Pennsylvania

Zip:

Country: United States

Financial Info

Stage:

series d

Raised Last:

$10M

Raised Total:

$65M

Social

Crunchbase

Metrics

0Website Global Rank

0Website Monthly Traffic

Twitter Followers

Description

Ceptaris Therapeutics, Inc. is a privately held, specialty pharmaceutical company that is developing a proprietary gel formulation of mechlorethamine hydrochloride for the treatment of early stage (stages I-IIA) mycosis fungoides, a type of Cutaneous T-Cell Lymphoma (CTCL). If approved, Ceptaris&s; investigational drug would be the first topical mechlorethamine product available to treat the signs and symptoms of this rare cancer.

Contact Phone:

Contact Email:

Investments

Announced Date	Company	Transaction	Money Raised

Funding Rounds

Announced Date	Transaction	Number of Investors	Money Raised	Lead Investors
11/2006	Series B	4	$4.5M	Ben Franklin Technology Partners of Southeastern Pennsylvania BioAdvance Osage Venture Partners TDH Capital Ben Franklin Technology Partners of Southeastern Pennsylvania BioAdvance Osage Venture Partners TDH Capital
11/2007	Series C	2	$14.5M	Palo Alto Investors Vivo Capital Palo Alto Investors Vivo Capital
2/2012	Debt Financing	2	$15M	Oxford Finance LLC Silicon Valley Bank Oxford Finance LLC Silicon Valley Bank
10/2010	Venture Round	1	-	BioAdvance BioAdvance
6/2002	Series A	1	$750k	Keyhorse Capital (KSTC)
2/2004	Venture Round	1	$500k	BioAdvance
8/2011	Series D	4	$14.4M	Aperture Venture Partners Burrill &a; Company Palo Alto Investors Vivo Capital Aperture Venture Partners Burrill &a; Company Palo Alto Investors Vivo Capital
8/2009	Venture Round		$3.1M
6/2012	Series D	7	$10M	Aperture Venture Partners BioAdvance Burrill &a; Company Osage Venture Partners Palo Alto Investors Third Point Ventures Vivo Capital Aperture Venture Partners BioAdvance Burrill &a; Company Osage Venture Partners Palo Alto Investors Third Point Ventures Vivo Capital
11/2010	Debt Financing	1	$2M	BioAdvance BioAdvance
10/2010	Venture Round	1	-	BioAdvance BioAdvance

Acquisitions

Announced Date	Name	Price

Employee Demographics

Employee Departments

Employee States

Similar Companies

Uniview Singapore VEID	Revenue: 0 - 100000 Employees: Industry: Software	Details
Konkuk University Medical Center	Revenue: 0 - 100000 Employees: 51 - 500 Industry: Education	Details
Daemon Technologies	Revenue: 0 - 100000 Employees: 1 - 10 Industry: Blockchain	Details
Ace International Trade	Revenue: 0 - 100000 Employees: 11 - 50 Industry: Industrial	Details
An Hòa Communications	Revenue: 0 - 100000 Employees: 1 - 10 Industry: Advertising	Details